Pfizer Inc., the world’s biggest drugmaker, won a court ruling that will block generic versions of its No. 1 product, Lyrica, in the U.S. until December 2018. Teva Pharmaceutical Industries Ltd. (TEVA), Actavis Plc (ACT) and Lupin Ltd. (LPC) are among the generic-drug makers that would infringe a valid patent on the pain medicine, the U.S. Court of Appeals for the Federal Circuit in Washington said in an opinion today on its website. The other generic-drug makers in the case were Sun Pharmaceutical Industries Ltd., Wockhardt Ltd. and Mylan Inc.
Help employers find you! Check out all the jobs and post your resume.
